Ranbaxy Laboratories http://www.globalpost.com/taxonomy/term/35924/all en India's Ranbaxy surprises with quarterly loss http://www.globalpost.com/dispatch/news/afp/130226/indias-ranbaxy-surprises-quarterly-loss <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's largest drug firm Ranbaxy reported Tuesday a sharp narrowing of its quarterly net loss but missed analyst forecasts for a profit after it was hit by product recall charges.</p> <p>The generics drug maker, majority-owned by Japan's Daiichi Sankyo, posted a net loss of 4.92 billion rupees ($91 million) for the three months to December, down from a loss of 29.83 billion rupees a year earlier.</p> <p>But analysts had expected Ranbaxy to be in the black for the fourth quarter and report a net profit of around 2.2 billion rupees, according to a poll by Dow Jones Newswires.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130226/indias-ranbaxy-surprises-quarterly-loss" target="_blank">read more</a></p> BSE Sensex Daiichi Sankyo Entertainment Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 26 Feb 2013 16:16:11 +0000 Agence France-Presse 5767366 at http://www.globalpost.com India's Ranbaxy shares climb as US legal battle ends http://www.globalpost.com/dispatch/news/afp/130514/indias-ranbaxy-shares-climb-us-legal-battle-ends <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in Ranbaxy climbed on Tuesday after US authorities slapped a $500 million fine on India's biggest drugmaker to settle a lengthy lawsuit over the sale of adulterated drugs in the United States.</p> <p>The case -- the largest-ever US drug safety settlement with a generic manufacturer -- ended eight years of criminal and civil investigations into the company, which is now majority-owned by Japan's Daiichi Sankyo.</p> <p>After opening down over four percent, Ranbaxy shares closed up 3.63 percent at 455.5 rupees as analysts said the decision would allow the firm to focus on the future.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130514/indias-ranbaxy-shares-climb-us-legal-battle-ends" target="_blank">read more</a></p> BSE Sensex Business Pharmaceutical sciences Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 14 May 2013 13:01:29 +0000 Agence France-Presse 5837451 at http://www.globalpost.com Japan's Daiichi says key details 'concealed' in Ranbaxy sale http://www.globalpost.com/dispatch/news/afp/130522/japans-daiichi-says-key-details-concealed-ranbaxy-sale <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>The Japanese owners of Ranbaxy on Wednesday accused former shareholders of the Indian company of concealing key information about a US probe into the safety of medicines made by the New Delhi-based firm.</p> <p>Last week, Ranbaxy Laboratories pleaded guilty in the United States to charges of making and distributing adulterated drugs at its two Indian plants of Paonta Sahib and Dewas and agreed to a $500 million settlement.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130522/japans-daiichi-says-key-details-concealed-ranbaxy-sale" target="_blank">read more</a></p> BSE Sensex Business Daiichi Sankyo Labor Law Ranbaxy Laboratories Ranbaxy Laboratories AFP Wed, 22 May 2013 19:30:16 +0000 Agence France-Presse 5844075 at http://www.globalpost.com Ranbaxy shares dive after Japan parent says was misled http://www.globalpost.com/dispatch/news/afp/130523/ranbaxy-shares-dive-after-japan-parent-says-was-misled <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares of Ranbaxy plunged Thursday after its Japanese parent accused former owners of the Indian firm of hiding key details about a US probe into the safety of drugs made by the generics giant.</p> <p>Last week, Ranbaxy Laboratories pleaded guilty in the United States to charges of making and distributing adulterated drugs at two Indian plants and agreed to a $500 million settlement.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130523/ranbaxy-shares-dive-after-japan-parent-says-was-misled" target="_blank">read more</a></p> BSE Sensex Business Daiichi Sankyo Labor Law Ranbaxy Laboratories Ranbaxy Laboratories AFP Thu, 23 May 2013 08:46:56 +0000 Agence France-Presse 5844494 at http://www.globalpost.com Indian drugmaker Ranbaxy faces new US regulation woes http://www.globalpost.com/dispatch/news/afp/130916/indian-drugmaker-ranbaxy-faces-new-us-regulation-woes-0 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in Indian generic drugs giant Ranbaxy Laboratories crashed as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.</p> <p>The FDA issued an alert on Friday against the factory in Mohali in the northern state of Punjab, spelling more bad news for Ranbaxy which is struggling to put a near decade-long history of US-led regulatory action behind it.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130916/indian-drugmaker-ranbaxy-faces-new-us-regulation-woes-0" target="_blank">read more</a></p> BSE Sensex Business Health Labor Law Pharmaceutical sciences Pharmacology Ranbaxy Laboratories Social Issues Technology AFP Mon, 16 Sep 2013 12:18:53 +0000 Agence France-Presse 5935491 at http://www.globalpost.com Indian drugmaker Ranbaxy faces new US regulation woes http://www.globalpost.com/dispatch/news/afp/130917/indian-drugmaker-ranbaxy-faces-new-us-regulation-woes <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.</p> <p>The FDA issued an alert on Friday against the factory at Mohali in the northern state of Punjab, spelling more bad news for Ranbaxy which is struggling to live down a nearly decade-long history of US-led regulatory action.</p> <p>Ranbaxy, one of the world's biggest generic drugs makers, slid 34.99 percent to a day's low of 297.25 rupees on the Bombay Stock Exchange in early trading.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130917/indian-drugmaker-ranbaxy-faces-new-us-regulation-woes" target="_blank">read more</a></p> BSE Sensex Business Health Labor Law Pharmaceutical sciences Pharmacology Ranbaxy Laboratories Social Issues Technology AFP Tue, 17 Sep 2013 11:48:59 +0000 Agence France-Presse 5935706 at http://www.globalpost.com India's Ranbaxy promises to address issues over US ban http://www.globalpost.com/dispatch/news/afp/130917/indias-ranbaxy-promises-address-issues-over-us-ban <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Ranbaxy Laboratories, one of world's biggest generic drug makers, said Tuesday it would take "all necessary steps" to help lift an import ban by the US health regulator on one of its factories.</p> <p>The US Food and Drugs Administration (FDA) issued an alert on Friday against the factory at Mohali in the northern state of Punjab, spelling more bad news for the company that has been marred by nearly 10 years of US-led regulatory action.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130917/indias-ranbaxy-promises-address-issues-over-us-ban" target="_blank">read more</a></p> BSE Sensex Business Labor Law Pharmaceutical sciences Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 17 Sep 2013 15:31:27 +0000 Agence France-Presse 5936388 at http://www.globalpost.com Ranbaxy taking 'stringent steps' to end US FDA ban http://www.globalpost.com/dispatch/news/afp/130921/ranbaxy-taking-stringent-steps-end-us-fda-ban <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines manufactured at its newly renovated showcase plant.</p> <p>The US Food and Drug Administration (FDA) banned imports last week from Ranbaxy's "ultra modern" Mohali plant, whose renovation was supposed to mark a turning point for the Indian generics giant after years of run-ins with US regulators.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130921/ranbaxy-taking-stringent-steps-end-us-fda-ban" target="_blank">read more</a></p> Business Labor Law Pharmaceutical industry Pharmaceutical sciences Pharmaceuticals policy Ranbaxy Laboratories Technology AFP Sat, 21 Sep 2013 13:31:20 +0000 Agence France-Presse 5940655 at http://www.globalpost.com Ranbaxy shares slide 9% on FDA woes http://www.globalpost.com/dispatch/news/afp/140113/ranbaxy-shares-slide-9-fda-woes <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares of one of India's biggest drugmakers, Ranbaxy Laboratories, slid by as much as nine percent Monday after a new warning from US drug regulators about its manufacturing practices. </p> <p>The New Delhi-based drug manufacturer's stock tumbled to 421.10 rupees before retracing some of its losses to close down 5.42 percent or 25.10 rupees at 438.35 rupees per share.</p> <p>Ranbaxy's three manufacturing plants are unable to ship to the United States, the company's key foreign market, due to FDA bans imposed earlier for failing to meet "good manufacturing practices".</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140113/ranbaxy-shares-slide-9-fda-woes" target="_blank">read more</a></p> Pharmaceutical industry Pharmaceutical sciences Pharmaceuticals policy Ranbaxy Laboratories Technology AFP Mon, 13 Jan 2014 14:50:05 +0000 Agence France-Presse 6041804 at http://www.globalpost.com India's Ranbaxy hit by new ban from US drug regulator http://www.globalpost.com/dispatch/news/afp/140124/indias-ranbaxy-hit-new-ban-us-drug-regulator <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in one of India's biggest drugmakers, Ranbaxy Laboratories, dropped 17 percent on Friday after the US Food and Drug Administration suspended imports from a fourth manufacturing facility of the firm.</p> <p>The FDA said it found significant violations from the expected "good manufacturing practice" requirements at Ranbaxy's Toansa factory in the northern state of Punjab.</p> <p>The New Delhi-based drug manufacturer's stock tumbled to 346.20 rupees from its previous close of 417.15 on the Bombay Stock Exchange.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140124/indias-ranbaxy-hit-new-ban-us-drug-regulator" target="_blank">read more</a></p> Pharmaceutical sciences Pharmaceuticals policy Pharmacology Ranbaxy Laboratories Technology AFP Fri, 24 Jan 2014 08:02:48 +0000 Agence France-Presse 6051750 at http://www.globalpost.com Shares of India's Ranbaxy slide 19% on new US FDA ban http://www.globalpost.com/dispatch/news/afp/140124/shares-indias-ranbaxy-slide-19-new-us-fda-ban <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in one of India's biggest drugmakers, Ranbaxy Laboratories, slid 19 percent Friday after the US Food and Drug Administration suspended imports from a fourth manufacturing plant of the firm.</p> <p>The FDA said Thursday it found significant violations from expected "good manufacturing practice" standards at Ranbaxy's Toansa factory in the northern state of Punjab.</p> <p>"Appropriate management action will be taken after completion of the internal investigation," Ranbaxy said Friday in response to the FDA statement.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140124/shares-indias-ranbaxy-slide-19-new-us-fda-ban" target="_blank">read more</a></p> Pharmaceutical industry Pharmaceutical sciences Pharmaceuticals policy Ranbaxy Laboratories Technology AFP Fri, 24 Jan 2014 16:48:19 +0000 Agence France-Presse 6052081 at http://www.globalpost.com Indian drug giant Ranbaxy trims losses but future is bleaker http://www.globalpost.com/dispatch/news/afp/140205/indian-drug-giant-ranbaxy-trims-losses-future-bleaker <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Ranbaxy Laboratories, India's biggest generic drugmaker by sales, reported a narrower quarterly loss on Wednesday thanks to rising sales in key markets and currency gains.</p> <p>But Ranbaxy, majority-owned by Japan's Daiichi Sankyo, faces an uphill battle to repeat the performance next quarter after the US Food and Drug Administration slapped another import ban on the company's products.</p> <p>The FDA announced the ban last month, citing concerns about "good manufacturing practice" at a plant in northern India. The move is expected to put severe pressure on future earnings.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140205/indian-drug-giant-ranbaxy-trims-losses-future-bleaker" target="_blank">read more</a></p> BSE Sensex Pharmaceutical sciences Ranbaxy Laboratories Ranbaxy Laboratories Technology AFP Wed, 05 Feb 2014 13:38:02 +0000 Agence France-Presse 6062206 at http://www.globalpost.com Indian drugmaker Ranbaxy suspends shipments after US bans http://www.globalpost.com/dispatch/news/afp/140225/indian-drugmaker-ranbaxy-suspends-shipments-after-us-bans <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Indian drugmaking giant Ranbaxy Laboratories said Tuesday it was suspending shipments from two of its plants following US import bans on its products over safety concerns.</p> <p>In a filing to the Bombay Stock Exchange, Ranbaxy said it was "temporarily putting on hold" shipments of active pharmaceutical ingredients from facilities at two of its plants -- Toansa in the northwest and Dewas in central India.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140225/indian-drugmaker-ranbaxy-suspends-shipments-after-us-bans" target="_blank">read more</a></p> BSE Sensex Business Madhya Pradesh Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 25 Feb 2014 15:10:32 +0000 Agence France-Presse 6080230 at http://www.globalpost.com India's Sun Pharma buys troubled drugmaker Ranbaxy in $4 billion deal http://www.globalpost.com/dispatch/news/the-canadian-press/140407/indias-sun-pharma-buys-troubled-drugmaker-ranbaxy-4-billion- <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> The Canadian Press </div> </div> </div> <!--paging_filter--><p>MUMBAI, India - India's Sun Pharmaceutical Industries says it is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion all-stock transaction.</p> <p>The combined company will be India's biggest pharmaceutical firm, with annual revenue estimated at $4.2 billion.</p> <p>Sun Pharma's shares rose 1.7 per cent Monday.</p> <p>Ranbaxy is the leading drugmaker in India's $26 billion generic pharmaceutical industry, but it has faced penalties from U.S. regulators for years. The U.S. has banned imports of drugs from two of its factories because of concerns over quality control.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.globalpost.com/terms-use#cp">Copyright 2014 Canadian Press.</a></p> <p>All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.</p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/the-canadian-press/140407/indias-sun-pharma-buys-troubled-drugmaker-ranbaxy-4-billion-" target="_blank">read more</a></p> BSE Sensex Business Economy of India Pharmaceutical sciences Ranbaxy Laboratories USD The Canadian Press Mon, 07 Apr 2014 09:46:46 +0000 The Canadian Press 6114958 at http://www.globalpost.com Indian drug maker Sun to buy troubled peer Ranbaxy for $4 bn http://www.globalpost.com/dispatch/news/afp/140407/indian-drug-maker-sun-buy-troubled-peer-ranbaxy-4-bn <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Top Indian drug giant Sun Pharmaceutical Industries said Monday it had agreed to buy its troubled peer Ranbaxy for $4.0 billion in stock, ending its ill-fated six-year control by Japan's Daiichi Sankyo.</p> <p>The deal will create India's biggest drugs manufacturer by far and leave Daiichi Sankyo with a significant stake in the combined entity.</p> <p>Daiichi Sankyo bought Ranbaxy in 2008, believing its dominance in cheap generic medicines and developing markets would help the firm grow.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140407/indian-drug-maker-sun-buy-troubled-peer-ranbaxy-4-bn" target="_blank">read more</a></p> BSE Sensex Business Economy of India Pharmaceutical sciences Ranbaxy Laboratories AFP Mon, 07 Apr 2014 11:36:16 +0000 Agence France-Presse 6115031 at http://www.globalpost.com